Search Results
Your search for 3 matches 16011 pages
Showing 151 - 200Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Living Guideline Adds Repotrectinib and Zongertinib as Treatment Options for Advanced NSCLC With Driver Alterations
ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI.1 The...
Early Histotripsy Use for Liver Tumors Raises Questions About Patient Selection
Histotripsy was cleared by the U.S. Food and Drug Administration in 2023 for the treatment of primary and metastatic liver tumors. In a research letter published in JAMA Network Open, Sears et al reported findings from a retrospective cohort study evaluating national practice patterns and...
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen...
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Our data on a triplet combination of chemotherapy, immune checkpoint inhibitors, and targeted therapy (ICTriplex) in advanced and refractory malignancies were presented in June at the 2026 ASCO Breakthrough Conference in Singapore. ICTriplex is a therapeutic strategy; it is not a single specific...
Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL
According to the results of a phase II study reported by Lynch et al in the Journal of Clinical Oncology, a chemotherapy-free approach using subcutaneous single-agent mosunetuzumab, or, for patients without an initial complete response, mosunetuzumab followed by polatuzumab vedotin plus...
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
Guest Editor’s Note: Cancer and its treatments often contribute to troubling symptoms, including fatigue, which has been correlated with poor treatment-related outcomes, including overall survival, in patients with cancer. Growing evidence indicates that mind-body therapies such as meditation,...
Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events
The addition of radium-223, an alpha-emitting bone-seeking radioisotope, to cabozantinib, a tyrosine kinase inhibitor, did not improve skeletal-related outcomes in patients with metastatic renal cell carcinoma and bone metastases, according to findings from the randomized phase II RADICAL trial...
Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses
“The future of cancer therapy lies in rational combinations that harness the immune system while preserving patient quality of life.” —Vincent T. DeVita, MD The treatment landscape for relapsed/refractory (R/R) multiple myeloma continues to evolve rapidly as T-cell–redirecting bispecific...
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Single-agent rezatapopt produced “very deep and durable responses” in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer, according to updated results from the pivotal phase II PYNNACLE trial presented at the 2026 ASCO Breakthrough meeting in Singapore. The analysis was...
High-Risk ERBB2-Negative Breast Cancer: Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy
The addition of dual PD-1 and LAG-3 inhibition with cemiplimab-rwlc and fianlimab to standard paclitaxel-based neoadjuvant chemotherapy resulted in improved pathologic complete response rates in patients with early-stage, high-risk ERBB2 (formerly HER2 or HER2/neu)-negative breast cancer, according ...
TACE Plus Thermal Ablation Improves Survival in Unresectable HCC
Transarterial chemoembolization (TACE) followed by thermal ablation was associated with improved survival outcomes compared with TACE alone in patients with liver-confined, unresectable hepatocellular carcinoma, according to findings from the phase III TORCH trial published by Lyu et al in JAMA...
Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer
In the phase III ARISTOTLE trial, adding irinotecan to preoperative capecitabine-based chemoradiotherapy did not improve disease-free survival in patients with locally advanced rectal cancer, and was also associated with substantially more severe toxicity. The findings were reported by...
Early Intravesical Pirarubicin Improves Relapse-Free Survival in Upper Tract Urothelial Carcinoma
A single intravesical dose of the antracycline pirarubicin administered within 24 hours after radical nephroureterectomy significantly improved relapse-free survival in patients with upper tract urothelial carcinoma. The benefit was driven mainly by fewer new bladder tumors after surgery, while...
Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma
First-line treatment with darovasertib plus crizotinib significantly improved progression-free survival and response rates compared with investigator’s choice of treatment in patients with HLA-A2–negative metastatic uveal melanoma, according to primary results from the phase IIb portion of the...
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
In the phase III BOND-003 Cohort C trial, intravesical cretostimogene grenadenorepvec, an oncolytic immunotherapy, produced complete responses in three-quarters of patients with high-risk, bacillus Calmette-Guérin (BCG)-unresponsive, non–muscle-invasive bladder cancer (NMIBC) with carcinoma in...
QOL Impact of Postmastectomy Chest Wall Radiotherapy: 5-Year Follow-up
In the 5-year quality-of-life (QOL) analysis of the phase III SUPREMO trial published in The Lancet Oncology, Velikova et al found that women with intermediate-risk breast cancer who received postmastectomy chest wall radiotherapy experienced modestly worse local chest wall symptoms at 5 years, but ...
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
On August 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to iberdomide (Zenbexus), a cereblon-modulating protein degrader (CELMoD), in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma who have received at least one ...
Darolutamide Plus Goserelin in AR-Positive Salivary Gland Carcinoma
Patients with androgen receptor (AR)–positive salivary gland carcinoma treated with darolutamide plus goserelin experienced greater antitumor activity than those treated with darolutamide alone in the Japanese phase II DISCOVARY trial, while both approaches demonstrated manageable safety profiles...
Does ctDNA-Guided Surveillance After Curative-Intent Surgery Benefit Outcomes in Cases of Recurrent Colorectal Cancer?
Dynamic surveillance using circulating tumor DNA (ctDNA) methylation testing after curative-intent surgery significantly increased the proportion of patients with recurrent nonmetastatic colorectal cancer who were able to undergo curative-intent treatment, according to results of the phase III FIND ...
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
In a phase Ib study published in the Journal of Clinical Oncology, Zhao et al found that the first-in-class bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren, BL-B01D1), which targets EGFR and HER3, demonstrated antitumor activity in patients with relapsed extensive-stage...
Phase III Trial Supports Intensified Total Neoadjuvant Therapy in High-Risk Rectal Cancer
In a multicenter Chinese randomized phase III trial published in the Journal of Clinical Oncology, Wang et al found that an intensified total neoadjuvant therapy approach integrating long-course radiotherapy with uninterrupted capecitabine and oxaliplatin chemotherapy improved disease-free survival ...
Technology-Enabled Intervention for HCT Recipients, Primary Care Doctors May Improve Skin Cancer Screening
Recipients of hematopoietic cell transplant (HCT) are at increased risk of skin cancer and screening for early detection is encouraged. New research published by Armenian et al in JNCCN—Journal of the National Comprehensive Cancer Network shows how a technology enabled, remotely delivered,...
Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma
In the phase III MajesTEC-9 trial, monotherapy with the bispecific antibody teclistamab kept disease under control substantially longer and improved overall survival compared with investigator’s choice of pomalidomide/bortezomib/dexamethasone (PVd) or carfilzomib/dexamethasone (Kd) in patients with ...
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
Adding the PD-L1 inhibitor durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance therapy delayed high-risk events and improved cystectomy-free survival in patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), according to expanded analyses from the phase...
FDA Approves Oncolytic Viral Therapy With Immunotherapy for Advanced Melanoma
On August 6, the U.S. Food and Drug Administration (FDA) granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who...
Trastuzumab Rezetecan Improves Progression-Free Survival in HER2-Positive Metastatic Breast Cancer
In the phase III HORIZON-Breast01 trial, the HER2-directed antibody-drug conjugate trastuzumab rezetecan significantly improved progression-free survival and showed a distinct safety profile vs pyrotinib plus capecitabine in HER2-positive metastatic breast cancer. The interim analysis, reported by...
Fusobacterium Positivity May Predict Relapse Risk, Benefit From Adjuvant Chemotherapy in Colorectal Cancer
When intratumoral Fusobacterium is found in surgical samples of colorectal cancer, the disease is typically more aggressive, with a weaker immune response and limited efficacy for adjuvant chemotherapy, making the cancer more likely to recur, according to findings from the multicenter FUSOMAP...
Durvalumab Plus Radiation Therapy in Frail Patients With Locally Advanced NSCLC
In a phase II study published in the Journal of Clinical Oncology, Rimner et al found that concurrent and consolidative durvalumab administered with definitive radiation therapy, without chemotherapy, demonstrated encouraging efficacy in patients with inoperable locally advanced non–small cell lung ...
HRR-Altered Metastatic Prostate Cancer: Talazoparib Plus Enzalutamide Improves Progression-Free Survival
In the phase III TALAPRO-3 trial, adding talazoparib to enzalutamide significantly improved imaging-based progression-free survival in patients with metastatic androgen pathway modulation–sensitive prostate cancer—also known as metastatic castration-sensitive prostate cancer—harboring homologous...
Combination Regimen Prolongs PFS in dMMR/MSI-H Metastatic Colorectal Cancer
The combination of mFOLFOX6, bevacizumab, and atezolizumab prolonged progression-free survival over atezolizumab monotherapy in the first-line setting for patients with mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer, according to findings from...
Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma
According to the results of a phase I study reported by Srour et al in the Journal of Clinical Oncology, the investigational allogeneic CD70-targeted chimeric antigen receptor (CAR) T-cell therapy ALLO-316 showed encouraging clinical activity with a manageable safety profile in heavily pretreated...
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
A few weeks ago, a friend in the United States reached out to me about her sister in Rwanda, a woman in her 40s with no history of smoking. Her chest pain had progressively worsened to the point of becoming unbearable. CT imaging revealed a concerning lung mass highly suggestive of malignancy. One...
TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
In a post hoc analysis of the global phase III TOPAZ-1 trial published in JAMA Oncology, Oh et al found that the addition of durvalumab to chemotherapy with gemcitabine and cisplatin was associated with long-term survival benefit and a clinically manageable safety profile in patients with...
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
In the phase III KEYNOTE-B15/EV-304 trial, perioperative enfortumab vedotin-ejfv plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response compared with the long-standing standard approach of neoadjuvant cisplatin plus gemcitabine in...
Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL
In a nonrandomized phase I trial published in JAMA Oncology, ultra low–dose interleukin (IL)-10–expressing chimeric antigen receptor (CAR) T-cell therapy (META 10-19) appeared to be safe and active in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Hu et al noted that...
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
On July 31, the U.S. Food and Drug Administration (FDA) approved lutetium-177–labeled PSMA-617 (vipivotide tetraxetan, also known as LuPSMA-617; Pluvicto), a targeted radionuclide therapy, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific...
Transplant Consolidation Improves Survival in Primary CNS Lymphoma
In the largest randomized trial in untreated primary central nervous system lymphoma to date, high-dose chemotherapy followed by autologous stem-cell transplantation improved progression-free and overall survival compared with nonmyeloablative consolidation in patients who responded to MATRix...
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
In the randomized phase III BRUIN CLL-322 trial, adding fixed-duration pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, to venetoclax-rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia or small lymphocytic ...
Case Series Supports High-Dose Oral Vitamin D for Cancer Therapy–Related Skin Toxicities
A retrospective multicenter case series published by Patil et al in JAMA Dermatology found high-dose oral vitamin D therapy to be associated with rapid symptomatic and objective improvement in chemotherapy- and radiation therapy–induced skin toxicities, without treatment-related adverse events....
Monica L. Baskin, PhD, Named Director of VCU Massey Comprehensive Cancer Center
Monica L. Baskin, PhD, will serve as the next Director of VCU Massey Comprehensive Cancer Center, pending approval by the Virginia Commonwealth University Board of Visitors in September. She is also expected to be named the Lipman Chair in Oncology. Dr. Baskin is the first female director of Massey ...
MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era
Among patients with high-risk hematologic malignancies who underwent hematopoietic cell transplantation with posttransplant cyclophosphamide, mismatched unrelated donor (MMUD) transplantation was associated with lower relapse rates than matched related donor (MRD) transplantation while showing...
Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS
Patients with previously untreated higher-risk myelodysplastic syndromes (MDS) did not experience improved outcomes with the addition of the anti-CD47 antibody magrolimab to azacitidine compared with azacitidine alone, according to the results of the phase III ENHANCE trial reported by Sallman et...
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
In an interim analysis of the phase III ELEVATE trial reported in The New England Journal of Medicine, Yue et al found that patients with completely resected ALK-positive non–small cell lung cancer (NSCLC) who received adjuvant ensartinib experienced significantly longer disease-free survival than...
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E–Positive Differentiated Thyroid Cancer
In a global phase III trial reported in The Lancet Oncology by Gao et al, dabrafenib plus trametinib significantly improved progression-free survival and overall response rate compared with placebo in previously treated patients with locally advanced or metastatic, radioactive iodine–refractory,...
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
In a phase I clinical trial, treatment with the investigational FcRH5×CD3 bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma—many of whom had already been through multiple other cancer treatments—and produced a median duration of response of 11.2 months ...
Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth
Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything about her as a scientist, a clinician, and a person. She was direct with compassion, generous to the ...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical questions: when ctDNA testing should (or should not) be used to (1) support cancer diagnosis; (2)...
Access Denied: Insurance Barriers to Biomarker Testing in Lung Cancer
In the past few decades, the rapidly growing field of precision medicine has improved the survival of patients with lung cancer. Yet the benefits of these therapies do not reach all patients. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, yet most patients are diagnosed ...
